Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...

People who are at a high risk for severe flu may be recommended antiviral treatment, whereas there is not a specific ...